EcoDrugPlus

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSCSEG00000002174
Gene Symbol: CYP3A65
1 Cross references
571 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSCSEG00000005330
Gene Symbol: LOC103388560
3 Cross references
178 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSCSEG00000013293
Gene Symbol: LOC103396420
3 Cross references
200 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSCSEG00000003211
Gene Symbol: LOC103387087
3 Cross references
215 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSCSEG00000014856
Gene Symbol: LOC103394287
3 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSCSEG00000008167
Gene Symbol: LOC103388561
3 Cross references
188 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSCSEG00000001376
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1

Ensembl ID : ENSCSEG00000006828
Gene Symbol: LOC103385091
3 Cross references
196 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSCSEG00000020206
Gene Symbol: LOC103386795
3 Cross references
196 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSCSEG00000017980
Gene Symbol: DPYD
3 Cross references
217 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCSEG00000010135
Gene Symbol: DDR2
3 Cross references
189 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCSEG00000007389
Gene Symbol: DDR2
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).